LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder

By LabMedica International staff writers
Posted on 30 Sep 2019
Image: In a new study, researchers uncovered a gene network that is disrupted in ASD, noting that the disrupted gene network is related to fetal brain development in ASD models (Photo courtesy of University of California, San Diego).
Image: In a new study, researchers uncovered a gene network that is disrupted in ASD, noting that the disrupted gene network is related to fetal brain development in ASD models (Photo courtesy of University of California, San Diego).
An improperly functioning molecular network and related biomarkers are expected to help doctors diagnose autism spectrum disorder in young children and to predict the likely severity of symptoms that may develop.

Autism spectrum disorder (ASD) comprises a range of neurodevelopmental mental disorders including autism and Asperger syndrome. Individuals “on the spectrum” often experience difficulties with social communication and interaction, and they often display restricted, repetitive patterns of behavior, interests, or activities. Symptoms are typically recognized between one and two years of age. Long-term problems may include difficulties in performing daily tasks, creating and keeping relationships, and maintaining a job.

ASD is usually diagnosed by subjective observation of clinical symptoms, and no reliable, practical, and objective markers of prognosis currently exist. Hundreds of genes have been implicated in ASD, but the mechanisms through which they contribute to the disorder have not been well defined.

Investigators at the University of California, San Diego (USA) extended the efforts aimed at developing objective tests for detection and prognosis of ASD by analyzing blood gene expression data from 302 one- to four-year-old boys with and without the diagnosis of ASD.

Results revealed the existence of a perturbed gene network that included genes that were highly expressed during fetal brain development. Furthermore, the degree of dysregulation in this network correlated with the severity of ASD symptoms in the toddlers. The network was also found to be dysregulated in ASD cellular models.

"The study shows that through analyses of gene expression from ordinary blood samples, it is possible to study aspects of ASD's fetal molecular origins, uncover the functional impact of hundreds of ASD risk genes that have been discovered over the years, and develop clinical tests of ASD diagnosis and severity prognosis," said senior author Dr. Nathan E. Lewis, associate professor of pediatrics and bioengineering at the University of California, San Diego. "The genetics of ASD are extremely heterogeneous. Hundreds of genes have been implicated, but the underlying mechanisms remain murky. These findings identify how ASD genetics dysregulate a core network that influences brain development at fetal and in the very early years of life and, consequently, the severity of later ASD symptoms."

The ASD study was published in the September 23, 2019, online edition of the journal Nature Neuroscience.

Related Links:
University of California, San Diego

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
ESR Analyzer
TEST1 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more